| Date Filed | Type | Description |
| 10/12/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/12/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 10/11/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/10/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/10/2023 |
8-K
| Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other E...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"AGREEMENT AND PLAN OF MERGER among: MIRATI THERAPEUTICS, INC., a Delaware corporation; BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation; and VINEYARD MERGER SUB INC.,",
"AMENDMENT TO BYLAWS OF MIRATI THERAPEUTICS, INC. ARTICLE XV MISCELLANEOUS",
"ARTICLE XV MISCELLANEOUS",
"Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio with Acquisition of Mirati Therapeutics",
"Voting and Support Agreement, by and among Bristol-Myers Squibb Company, Boxer Capital, LLC, and MVA Investors, LLC" |
|
| 10/10/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/10/2023 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 10/05/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 10/02/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 08/23/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/16/2023 |
SC 13D/A
| Boxer Capital, LLC reports a 15.9% stake in Mirati Therapeutics, Inc. |
| 08/09/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/09/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/08/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results, Appointed a new director |
| 07/21/2023 |
8-K
| Quarterly results |
| 05/24/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/12/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results |
| 04/06/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/05/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 02/28/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/28/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 3.8% stake in Mirati Therapeutics, Inc. |
| 02/14/2023 |
SC 13G
| ARMISTICE CAPITAL, LLC reports a 6.1% stake in Mirati Therapeutics, Inc. |
| 02/14/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 8.6% stake in Mirati Therapeutics Inc. |
| 02/06/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/09/2023 |
8-K
| Investor presentation |
| 12/12/2022 |
8-K
| Quarterly results |
| 12/05/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
|